Revolutionary Medicines Catalyzed by Protein Degradation
Kymera Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation to develop oral small molecule medicines addressing critical health problems in immunology and oncology. Its proprietary platform enables degradation of disease-causing proteins, transforming treatment paradigms for undruggable targets.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2025
Jan 2024
Aug 2020
Mar 2020
Nov 2018
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
